Commedson Beijing Pharmaceutical Technology Co.
Commedson Beijing Pharmaceutical Technology Co. provides end-to-end computational drug discovery services to biotech and pharma clients. They use ultra-large-scale 3D structure-based virtual screening, AI-enhanced workflows, and medicinal chemistry to identify and optimize small-molecule leads. The platform integrates novel X-ray crystallography/cryo-EM structures, large docking screening methods, a hierarchical lead optimization pipeline, and AI/ML algorithms to support hit discovery, lead optimization, feasibility assessments, and project management for biotech and pharmaceutical partners. This approach combines computational chemistry, structure-based screening, AI/ML, and lead-optimization pipelines to accelerate first-in-class drug discovery while reducing costs. The company targets the biotech and pharmaceutical markets with a platform-driven service model for end-to-end drug discovery.
Commedson Beijing Pharmaceutical Technology Co.
Commedson Beijing Pharmaceutical Technology Co. provides end-to-end computational drug discovery services to biotech and pharma clients. They use ultra-large-scale 3D structure-based virtual screening, AI-enhanced workflows, and medicinal chemistry to identify and optimize small-molecule leads. The platform integrates novel X-ray crystallography/cryo-EM structures, large docking screening methods, a hierarchical lead optimization pipeline, and AI/ML algorithms to support hit discovery, lead optimization, feasibility assessments, and project management for biotech and pharmaceutical partners. This approach combines computational chemistry, structure-based screening, AI/ML, and lead-optimization pipelines to accelerate first-in-class drug discovery while reducing costs. The company targets the biotech and pharmaceutical markets with a platform-driven service model for end-to-end drug discovery.